KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Assets (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Assets data on record, last reported at $11.7 billion in Q4 2025.

  • For Q4 2025, Assets fell 2.94% year-over-year to $11.7 billion; the TTM value through Dec 2025 reached $11.7 billion, down 2.94%, while the annual FY2025 figure was $11.7 billion, 2.94% down from the prior year.
  • Assets reached $11.7 billion in Q4 2025 per JAZZ's latest filing, up from $11.4 billion in the prior quarter.
  • Across five years, Assets topped out at $13.2 billion in Q2 2021 and bottomed at $6.8 billion in Q1 2021.
  • Average Assets over 5 years is $11.3 billion, with a median of $11.4 billion recorded in 2025.
  • Peak YoY movement for Assets: skyrocketed 117.8% in 2021, then fell 16.78% in 2022.
  • A 5-year view of Assets shows it stood at $12.3 billion in 2021, then decreased by 11.9% to $10.8 billion in 2022, then increased by 5.15% to $11.4 billion in 2023, then increased by 5.43% to $12.0 billion in 2024, then dropped by 2.94% to $11.7 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $11.7 billion in Q4 2025, $11.4 billion in Q3 2025, and $10.9 billion in Q2 2025.